The Study of External Dose Rate and Retained Body Activity of Patients Receiving ¹³¹I Therapy for Differentiated Thyroid Carcinoma

By Zhang Haiying   Jiao Ling   Cui Songye   Wang Liang   Tan Jian   Zhang Guizhi   He Yajing   Ruan Shuzhou   Fan Saijun   Zhang Wenyi  

International Journal of Environmental Research and Public Health, Vol. 11, Iss. 10, 2014-10 ,pp. : 10991-11003

MDPI

Access to resources Recommend Favorite

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy

By Kesavan Murali   Boucek Jan   MacDonald William   McQuillan Andrew   Turner J. Harvey  

Diagnostics, Vol. 7, Iss. 2, 2017-05 ,pp. : 26-26

MDPI

Access to resources Recommend Favorite

Phase I Study of Weekly Irinotecan Combined with Weekly Cisplatin in Patients with Advanced Solid Tumors

By  

Chemotherapy, Vol. 48, Iss. 4, 2002-09 ,pp. : 205-210

Karger

Access to resources Recommend Favorite

The Effect of Diagnostic Absorbed Doses from ¹³¹I on Human Thyrocytes in Vitro

By Adamczewski Zbigniew   Stasiołek Mariusz   Karwowski Bolesław   Dedecjus Marek   Orszulak-Michalak Daria   Merecz Anna   Śliwka Przemysław W.   Puła Bartosz   Lewiński Andrzej  

International Journal of Molecular Sciences, Vol. 16, Iss. 7, 2015-06 ,pp. : 14608-14622

MDPI

Access to resources Recommend Favorite

High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin

By Bortolotti Massimo   Bolognesi Andrea   Battelli Maria Giulia   Polito Letizia  

Toxins, Vol. 8, Iss. 6, 2016-06 ,pp. : 192-192

MDPI

Access to resources Recommend Favorite